financetom
Business
financetom
/
Business
/
Synopsys Lowers Fiscal 2025 Earnings Guidance on China Challenges, Missed Contract Opportunity, Deutsche Bank Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Synopsys Lowers Fiscal 2025 Earnings Guidance on China Challenges, Missed Contract Opportunity, Deutsche Bank Says
Sep 10, 2025 8:09 AM

10:50 AM EDT, 09/10/2025 (MT Newswires) -- Synopsys ( SNPS ) reset its guidance in its fiscal Q3 results as its "good" performance in its core electronic design automation business was overshadowed by challenges in China and the failure to close a major contract, Deutsche Bank said in a note emailed Wednesday.

The company on late Tuesday slashed its fiscal 2025 non-GAAP EPS guidance to a range of $12.76 to $12.80 from the previous range of $15.11 to $15.19. Revenue projection for the fiscal year was raised to $7.03 billion to $7.06 billion from prior range of $6.75 billion to $6.81 billion.

Synopsys' ( SNPS ) sales in China were weaker than expected, largely due to the lingering impact of a six-week export ban on semiconductor equipment to China by the US Bureau of Industry and Security, which delayed the decision-making of local customers, Deutsche Bank analysts said.

Synopsys ( SNPS ) also invested significantly in developing intellectual property for a major foundry client believed to be Intel ( INTC ) , but the anticipated contract with the client did not materialize, causing a shortfall in revenue, the analysts said. The company expects this issue to impact results in Q4 and beyond, according to the note.

Further, Synopsys ( SNPS ) is looking to reduce its global headcount by 10% by the end 2026, targeting a better cost structure after its acquisition of Ansys, the analysts noted.

Deutsche Bank's rating on the company's stock is buy with a price target of $580.

Price: 399.80, Change: -204.57, Percent Change: -33.85

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Novartis: launch of Morphosys drug by could be 2027 or later
Novartis: launch of Morphosys drug by could be 2027 or later
Nov 21, 2024
FRANKFURT, Nov 21 (Reuters) - Novartis' CEO said on Thursday that the delayed launch of blood-cancer drug pelabresib from the takeover of Morphosys could be achieved in 2027 or later, but any approval would depend on further safety data. It will take us at least until 2027. It might take longer, depending on the safety topic. And of course there...
FAA plans to review 737 MAX engine issue after bird strike incidents
FAA plans to review 737 MAX engine issue after bird strike incidents
Nov 21, 2024
WASHINGTON, Nov 21 (Reuters) - The Federal Aviation Administration plans to convene a review board in the coming weeks to consider safety concerns about engines on Boeing 737 MAX airplanes after two bird strike incidents on Southwest Airlines ( LUV ) planes in 2023. The FAA said it is addressing an issue with the CFM LEAP-1B engine and is collaborating...
Volkswagen enters third round of wage talks as strikes loom
Volkswagen enters third round of wage talks as strikes loom
Nov 21, 2024
WOLFSBURG (Reuters) -Volkswagen management and worker representatives begin a third round of wage negotiations on Thursday, with just ten days left to find a solution before unions have threatened strikes across German sites. The talks are over wages for 120,000 of Volkswagen's roughly 300,000 staff in Germany, employed at six plants governed by a separate collective wage agreement to the...
CTS Eventim's 9-month revenue crosses 2 bln euros for the first time
CTS Eventim's 9-month revenue crosses 2 bln euros for the first time
Nov 21, 2024
Nov 21 (Reuters) - CTS Eventim on Thursday said its revenue surpassed 2 billion euros ($2.1 billion) for the first time in a nine-month period this year, driven by its diverse ticketing portfolio and expansion both organically and through acquisitions. Despite challenging economic conditions and high costs, CTS Eventim still expects its adjusted core profit to increase significantly in 2024....
Copyright 2023-2026 - www.financetom.com All Rights Reserved